Moffitt Cancer Center | Strategic Alliance Partners

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.

IDO is a key enzyme in the normal regulation of the host's adaptive immune response. Its role in regulating the immune response was initially demonstrated when pregnant mice were given IDO inhibitors, resulting in the rejection of the unborn fetus by the maternal immune system.

Adverse events associated with ipilimumab for the treatment of metastatic melanoma are better understood after further analysis of clinical trial data that led to the FDA's 2011 approval of the drug.

Arnold B. Etame, MD, PhD, from the Moffitt Cancer Center, describes stereotactic neuronavigation, which may offer more surgical visualization capabilities for the neurosurgeon.

Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses the use of ziv-aflibercept (Zaltrap) for patients with metastatic colorectal cancer.

Patients receiving transplants from unrelated donors to treat various hematologic malignancies may benefit more from receiving adult stem cells harvested from bone marrow rather than peripheral-blood stem cells (the current standard).

Jeffrey S. Weber, MD, PhD, specializes in cancer immunotherapy and has been involved in numerous trials of clinical drug development, vaccines, and studies on autoimmunity and melanoma.

Drugs that target the programmed death-1 pathway hold considerable promise for the treatment of patients with melanoma, particularly in integrating the agents into the sequence of therapy.

Paul Jacobsen, from the H. Lee Moffitt Cancer Center and Research Institute, Discusses Survivorship Care Plans

Located in Tampa, Florida, Moffitt Cancer Center enjoys a reputation as one of the world's most sophisticated cancer centers.

A combination of immunotherapy and fractionated external-beam radiation therapy provided tumor-specific immune responses in patients with soft-tissue sarcoma.